Biopiracy and psychedelics: to what degree should Western pharmaceutical companies fairly compensate indigenous peoples?
#92 Biopiracy of indigenous people’s psychoactive substances Read More »
Contact and communication with other realms will have to become structured, normalized, and repeated for what comes after initial contact.
#91 Otherworldly embassies, stock exchanges, and general meeting points Read More »
Do all carbon-based ecosystems produce visionary compounds as a kind of “calling card” to contact and communicate with other sentient beings?
#90 Hyperdimensional calling cards on Earth and elsewhere Read More »
I highly recommend working with Plant Medicine Law Group if you work with psychedelics in any way. Cover those bases!
Dr. Michael Marder draws on his knowledge of plant phenomenology in speculating what it is like to be a psychedelic plant.
Dr. Felix Krengel explains the botany of ibogan-type-alkaloid-containing Apocynaceae plant species and his latest extraction research.
#87 ep3.5_Alternative Botanical Sources of Ibogan Alkaloids_Felix Krengel Read More »
Dr. Chris Jenks speaks about his discovery of “total alkaloid (TA) extract” and iboga alkaloid extraction and purification methods.
#86 ep3.4_TA Extract and HCl Methods and History_Chris Jenks Read More »
Dr. Surajit Sinha speaks about his research into non-ibogaine iboga-type minor alkaloids that get far less attention compared to ibogaine.
#85 ep3.3_Non-ibogaine Iboga Alkaloids_Surajit Sinha Read More »
Dr. Lowan H. Stewart and I discuss dissociativeness and other overlaps between ketamine and iboga, both NMDA antagonists.
#84 ep3.2_Ketamine-Iboga Connection – NMDA_Lowan H. Stewart Read More »
Dr. Peter H. Addy and I compare notes on the neuroscience and phenomenology of Salvia divinorum and iboga, both kappa opioid agonists.
#83 ep3.1_Salvia-Iboga Connection – Kappa Opioid_Peter H. Addy Read More »